DE-117 ophthalmic solution + Timolol ophthalmic solution
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Open Angle Glaucoma or Ocular Hypertension
Conditions
Open Angle Glaucoma or Ocular Hypertension
Trial Timeline
Jul 1, 2016 โ Nov 9, 2017
NCT ID
NCT02822729About DE-117 ophthalmic solution + Timolol ophthalmic solution
DE-117 ophthalmic solution + Timolol ophthalmic solution is a phase 3 stage product being developed by Santen Pharmaceutical for Open Angle Glaucoma or Ocular Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT02822729. Target conditions include Open Angle Glaucoma or Ocular Hypertension.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02822729 | Phase 3 | Completed |
Competing Products
20 competing products in Open Angle Glaucoma or Ocular Hypertension
Other Products from Santen Pharmaceutical
Eybelis ophthalmic solution 0.002%Approved
85
Aflibercept Injection [Eylea]Approved
85
STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%Phase 3
77
DE-117B Eye Drops + LatanoprostPhase 3
77
3% DE-089 ophthalmic solution + 0.1% sodium hyaluronate ophthalmic solutionPhase 3
77